Shares of GlaxoSmithKline PLC (NYSE:GSK) have been assigned a consensus recommendation of “Hold” from the twenty-two ratings firms that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation and ten have given a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $45.67.

Several equities analysts have issued reports on the stock. TheStreet cut shares of GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research report on Wednesday, July 26th. Citigroup Inc. restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Thursday, July 27th. BidaskClub cut shares of GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a research report on Monday, July 24th. J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Monday, July 24th. Finally, Zacks Investment Research cut shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Friday, July 21st.

Several large investors have recently bought and sold shares of GSK. 10 15 Associates Inc. boosted its stake in GlaxoSmithKline PLC by 6.4% in the first quarter. 10 15 Associates Inc. now owns 237,716 shares of the pharmaceutical company’s stock worth $10,022,000 after buying an additional 14,247 shares during the last quarter. Lincluden Management Ltd. boosted its stake in GlaxoSmithKline PLC by 1.7% in the first quarter. Lincluden Management Ltd. now owns 120,845 shares of the pharmaceutical company’s stock worth $5,095,000 after buying an additional 1,990 shares during the last quarter. Anchor Capital Advisors LLC boosted its stake in GlaxoSmithKline PLC by 9.6% in the first quarter. Anchor Capital Advisors LLC now owns 613,324 shares of the pharmaceutical company’s stock worth $25,858,000 after buying an additional 53,894 shares during the last quarter. BlueCrest Capital Management Ltd boosted its stake in GlaxoSmithKline PLC by 293.5% in the first quarter. BlueCrest Capital Management Ltd now owns 51,157 shares of the pharmaceutical company’s stock worth $2,157,000 after buying an additional 38,157 shares during the last quarter. Finally, Roundview Capital LLC boosted its stake in GlaxoSmithKline PLC by 157.4% in the first quarter. Roundview Capital LLC now owns 24,529 shares of the pharmaceutical company’s stock worth $1,034,000 after buying an additional 15,000 shares during the last quarter. Institutional investors own 8.96% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “GlaxoSmithKline PLC (NYSE:GSK) Receives Average Recommendation of “Hold” from Analysts” was published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/08/08/glaxosmithkline-plc-nysegsk-receives-average-recommendation-of-hold-from-analysts.html.

Shares of GlaxoSmithKline PLC (GSK) traded down 0.37% during mid-day trading on Tuesday, hitting $40.15. 2,272,250 shares of the company were exchanged. The firm has a market capitalization of $98.13 billion, a P/E ratio of 39.60 and a beta of 1.03. The company’s 50-day moving average price is $42.44 and its 200-day moving average price is $41.81. GlaxoSmithKline PLC has a 12-month low of $37.20 and a 12-month high of $44.59.

GlaxoSmithKline PLC (NYSE:GSK) last announced its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.68 by $0.02. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. The firm had revenue of $9.36 billion during the quarter, compared to analysts’ expectations of $9.52 billion. Equities research analysts predict that GlaxoSmithKline PLC will post $2.85 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 12th. Stockholders of record on Friday, August 11th will be given a dividend of $0.491 per share. The ex-dividend date is Wednesday, August 9th. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $1.96 annualized dividend and a dividend yield of 4.89%. GlaxoSmithKline PLC’s dividend payout ratio is 194.00%.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.